Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Empagliflozin 10 mg Tablets in Healthy Thai Volunteers
NCT06308679Phase 1Not yet recruiting
- Sponsor
- Pharma Nueva
- Start
- May 2024
- Primary completion
- May 2024
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, open-label trial of empagliflozin in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Pharma Nueva. Primary endpoints: Plasma Area Under the Curve (AUC(0-48hr)) and Peak Plasma Concentration. Planned start May 2024; status: not yet recruiting.
02
Drugs
empagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT06308679.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06308679.